Fidaxomicin + Vancomycin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Clostridium Difficile Infection (CDI)
Conditions
Clostridium Difficile Infection (CDI)
Trial Timeline
May 1, 2017 → Jun 23, 2021
NCT ID
NCT02692651About Fidaxomicin + Vancomycin
Fidaxomicin + Vancomycin is a approved stage product being developed by Merck for Clostridium Difficile Infection (CDI). The current trial status is completed. This product is registered under clinical trial identifier NCT02692651. Target conditions include Clostridium Difficile Infection (CDI).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02692651 | Approved | Completed |
Competing Products
20 competing products in Clostridium Difficile Infection (CDI)